⌕
Aktis Oncology · AKTS · Nasdaq
Tenet 52 · Mixed
Compare
$16.16−2.77%At closeTenet 52 · Mixed
$16.16−0.46 (−2.77%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Aktis Oncology (AKTS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue history is too short to read a growth trend, net margin −980.9%. Worth your attention in FY25: Share count (+50.6%) and Capex step-up ($9.6M). Both visible in the receipts below.
The four lines that matter · FY22–FY25
Revenue ($M)▲336.9%
6.5
FY22→FY25CAGR —
Net income ($M)▼44.9%
−63.7
FY22→FY25CAGR —
Free cash flow ($M)—
−73.7
capex stepped upCAGR —
Diluted EPS▲5.6%
−1.19
FY22→FY25CAGR —
What the receipts whisper · what a headline number hides
Stock comp vs FCF
−7.0%

of free cash flow goes to stock comp (was −3.4% in FY22). Owner-earnings math treats it as a real cost.

Share count
+50.6%

34.9mn → 52.5mn diluted shares since FY22. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$9.6M

▲235% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

Returns vs FCF
n/m

$0.0M returned vs $−73.7M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY22–FY25
Where every revenue dollar goes · FY25 ($M)6.5Revenue0.0COGS6.5Gross profit−67.5R&D−12.6SG&A−74.7Op income11.0Tax & other−63.7Net income

-981¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%FY22FY25

Net margin -980.9% is below the sector median.

The receipt · income statement · FY22–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemFY25FY24FY23FY22YoYCAGR 22→25
Revenue & profitability
Revenue
6.51.50.00.0▲336.9%—
Cost of revenue
0.00.00.00.0——
Gross profit
6.51.50.00.0▲336.9%—
Research & development
67.541.025.914.3▲64.7%+67.7%
Selling, general & admin
12.611.37.75.1▲11.4%+35.1%
Total operating expenses
81.253.534.819.8▲51.6%+60.1%
Operating incomefeeds ROC rank
−74.7−52.0−34.8−19.8▼43.5%—
Other income, net
11.08.16.21.8——
Pretax income
−63.7−44.0−28.6−17.9▼44.9%—
Income tax
0.00.00.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−63.7−44.0−28.6−17.9▼44.9%—
Per share
Diluted EPSbuyback-sensitive
−1.19−1.26−0.82−0.51▲5.6%—
Diluted shares (mn)
52.5234.8634.8634.86▲50.6%+14.6%
Margins
Gross margin82nd pct in Healthcare
100.0%100.0%——▲0.0pp—
Operating margin
−1149.5%−3500.3%——▲2350.8pp—
Net margin8th pct in Healthcare
−980.9%−2957.6%——▲1976.7pp—
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2025-12-31 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Aktis Oncology's revenue last fiscal year?

Aktis Oncology reported revenue of $6.5M in fiscal 2025, up 336.9% from fiscal 2024.

What was Aktis Oncology's net income?

Aktis Oncology reported net income of −$63.7M in fiscal 2025, a net margin of −980.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.